Of note, state-of-the-art renewal has indicated the oncogenic role of RUNX2 in multiple cancer types (16–18), which the expression pattern and regulatory mechanism during chemoresistance in triple negative breast cancer are largely indistinct. This evidence concerns the gene RUNX2 and cancer.